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Abstract
Inadequate dietary Zn consumption increases susceptibility to esophageal and 
other cancers in humans and model organisms. Since Zn supplementation can 
prevent cancers in rodent squamous cell carcinoma (SCC) models, we were 
interested in determining if it could have a preventive effect in a rodent skin 
cancer model, as a preclinical basis for considering a role for Zn in prevention 
of human nonmelanoma skin cancers, the most frequent cancers in humans. 
We used the 7,12- dimethyl benzanthracene carcinogen/phorbol myristate acetate 
tumor promoter treatment method to induce skin tumors in Zn- sufficient wild- 
type and Fhit (human or mouse protein) knockout mice. Fhit protein expression 
is lost in >50% of human cancers, including skin SCCs, and Fhit- deficient mice 
show increased sensitivity to carcinogen induction of tumors. We hypothesized 
that: (1) the skin cancer burdens would be reduced by Zn supplementation; 
(2) Fhit−/−(Fhit, murine fragile histidine triad gene) mice would show increased 
susceptibility to skin tumor induction versus wild- type mice. 30 weeks after 
initiating treatment, the tumor burden was increased ~2- fold in Fhit−/− versus 
wild- type mice (16.2 versus 7.6 tumors, P < 0.001); Zn supplementation sig-
nificantly reduced tumor burdens in Fhit−/− mice (males and females combined, 
16.2 unsupplemented versus 10.3 supplemented, P = 0.001). Most importantly, 
the SCC burden was reduced after Zn supplementation in both strains and 
genders of mice, most significantly in the wild- type males (P = 0.035). Although 
the mechanism(s) of action of Zn supplementation in skin tumor prevention 
is not known in detail, the Zn- supplemented tumors showed evidence of reduced 
DNA damage and some cohorts showed reduced inflammation scores. The re-
sults suggest that mild Zn supplementation should be tested for prevention of 
skin cancer in high- risk human cohorts.
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Introduction
About 2 million people in the United States are diagnosed 
and treated for nonmelanoma skin cancer (NMSC) yearly, 
making it the most common form of cancer [1], and in 
2012, there were nearly 100,000 cases registered in Great 
Britain [2–5]. The majority of NMSCs are basal cell car-
cinomas (BCC) or squamous cell carcinomas (SCCs) [6]. 
Among humans, both BCC and SCC are more common 
in males than females, with a wider sex difference for SCC 
[6]. SCC incidence in Great Britain increased by more 
than a third in males and females from 2002 to 2010, 
likely reflecting increased UV exposure [6]. NMSCs have 
high cure rates due to visible precancerous lesions, treat-
ment with various surgical methods and follow- up histo-
pathological analysis for confirmation of complete excision. 
Since most skin cancers occur on visible portions of the 
skin, the treatment methods can lead to considerable scar-
ring of facial and other highly visible areas. Radiation therapy 
and topical chemotherapies are alternatives for more 
advanced cancers [7]. Due to the curability of NMSC, it 
is generally not included in overall cancer statistics; however 
it can be fatal: ~2000 individuals die annually from NMSC 
in the U.S. alone. Although NMSCs metastasize infrequently, 
immunosuppressed patients or those on immunosuppressive 
medications (transplant patients) are at a 100- fold higher 
risk of NMSC- associated morbidity [8], with some patients 
developing hundreds of skin cancers. Thus, we sought to 
confirm a prevention method that would provide additional 
protection, particularly for fair- skinned and immunosup-
pressed populations, a method that may prove efficacious 
for other cancers as well.
Zinc (Zn) is an essential trace element in man and 
animals, required for activity of ~2000 transcription fac-
tors and >300 enzymes [9]. Dietary Zn deficiency has 
been linked to many human cancers, including esophageal 
SCC [10], head and neck [11], and digestive tract cancers 
[12]. Likewise, studies of rodent models of chemically 
induced esophageal and forestomach cancers have shown 
that Zn deficiency results in significantly more tumors 
and more severe histopathological lesions [13, 14]. Zn 
supplementation and replenishment in these Zn- deficient 
animal models reversed tumor burdens and histopatho-
logical grade. In a recent study, we maintained Zn- deficient 
and Zn- sufficient mice on a regimen of Zn supplementa-
tion in the drinking water and found that even the Zn- 
sufficient cohort benefited significantly from supplemental 
Zn during forestomach carcinogenesis, resulting in 
decreases in tumor number and severity of preneoplastic 
and neoplastic lesions [14].
We have also questioned whether Zn has antitumor 
efficacy in a Zn- sufficient animal by investigating in Zn- 
sufficient rats the efficacy of Zn supplementation on the 
progression of tongue SCC induced by exposure to 
4- nitroquinoline 1- oxide in drinking water. Zn supple-
mentation significantly reduced the incidence of papillomas 
and invasive carcinomas. The results demonstrated that 
Zn supplementation has chemopreventive efficacy against 
oral carcinogenesis in nutritionally complete animals, sug-
gesting that Zn supplementation may be efficacious in 
the chemoprevention of human oral cancer [15].
Since Zn is an inexpensive supplement, readily available 
in developed countries, and could easily be included in 
human clinical trials, we set out to determine whether 
Zn supplementation would lower tumor burdens in a 
mouse NMSC preclinical model.
We chose to induce NMSC using the well- characterized 
model for studying premalignant and malignant progres-
sion, the 7,12- dimethyl benzanthracene/phorbol myristate 
acetate (DMBA/PMA) regimen [16]. DMBA is oxidized 
by endogenous P450 enzymes to metabolites that form 
covalent DNA adducts. It is used to induce skin cancer 
in conjunction with PMA, a phorbol, which activates the 
signal transduction enzyme, protein kinase C, and pro-
motes tumor development [17]. We began these studies 
using C57BL/6J (B6) wild- type (wt) mice that are naturally 
resistant to skin cancers (http://www.informatics.jax.org/
mtbwi/tumorFrequencyGrid.do); we included (Fhit, murine 
fragile histidine triad gene) Fhit−/− mice on the B6 back-
ground, because Fhit (human or mouse protein) loss has 
been reported for skin SCCs [18, 19]. We hypothesized 
that they would show enhanced sensitivity to induction 
of skin cancers versus the B6 strain. Fhit knockout mice 
have shown enhanced sensitivity to carcinogen induction 
of gastric and lung cancers [20–22], so we considered 
that this strain would provide a strong test of the Zn 
supplementation effect. Also, loss of expression of Fhit 
tumor suppressor protein occurs in >50% of human can-
cers [23]. Fhit also serves as a genome caretaker preventing 
the onset of global genome instability [24, 25]. Fhit- deficient 
and haploinsufficient mice spontaneously develop lung 
tumors, lymphomas and liver hemangiomas at slightly 
higher incidences than wt mice [21] and 100% of Fhit 
knockout mice developed NMBA- induced forestomach 
tumors, significantly more than wt mice [20, 21]. We 
hypothesized that wt and Fhit- deficient mice would develop 
increased numbers of induced NMSCs and that Zn sup-
plementation would reduce tumor burdens.
Materials and Methods
Mouse strain, tumor induction, and Zn 
supplementation
Wild- type B6 and Fhit−/− mice were examined for skin 
cancer susceptibility. B6 mice were from the Jackson 
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Laboratory. Fhit−/− mice (~95% B6 genetic makeup) were 
generated as described [14, 26], backcrossed to B6 mice 
and carried as homozygous knockout mice; genotypes were 
confirmed before tumor induction. Mouse studies and 
experimentation were carried out according to protocols 
approved by the Ohio State University Institutional Animal 
Care and Use Committee. To induce tumors, the dorsal 
skin of 6–8- week- old mice was shaved to provide a 
3 × 5 sq. cm area of skin for topical treatment with 
50 μg of DMBA (Sigma, St. Louis, MO) in 200 μL acetone, 
followed by application of 7.5 μg PMA (Sigma) 3 times/
week for 30 weeks. A 20- week pilot experiment was first 
performed on small cohorts using the same mouse strains 
and treatment protocol without Zn supplementation, to 
gage timing of tumor initiation in the different mouse 
strains and genders (see Fig. 1A for graph of tumor ini-
tiation/latency in the first 20 weeks, without Zn supple-
mentation). For the 30 week experiment, each genotype 
included control and Zn- supplemented cohorts with mouse 
groups ranging from 10 to 28 mice. Control mice received 
standard water ad libitum, whereas the treatment group 
received Zn- gluconate (Life Extension, Ft. Lauderdale, FL) 
supplemented water (0.043 mg Zn/day/mouse, assuming 
~7 mL water/day/mouse (equivalent to ~120 mg Zn/day 
for a human), following the initial DMBA treatment. All 
mice were fed standard lab rodent diet (Harlan Teklad 
Figure 1. Timing of tumor induction and histopathology of DMBA/PMA- induced skin tumors in mice with or without Zn supplementation. (A) Line 
graph showing the average number of tumors in wt and Fhit−/− male and female mice 4–19.5 weeks after treatment with DMBA. The data was from 
of a pilot study with 2–6 mice per group to estimate timing of tumor initiation in the mouse cohorts. (B) Representative photomicrographs of H&E 
stained skin lesions showing (a) a papilloma from a Fhit−/− female without Zn; (b) mild hyperplasia from a wt male with Zn treatment; (c) a severe 
hyperplasia from a Fhit−/− female with Zn treatment; (d) dysplasia from a Fhit−/− female with Zn treatment; (e) a poorly differentiated SCC with cords 
of highly atypical tumor cells diffusely infiltrating into the stroma and skeletal muscle from a Fhit−/− female without Zn; (f) a well- differentiated SCC, 
with mild cytologic atypia from a wt female without Zn; (g) a moderately differentiated SCC, with enlarged tumor cells and prominent nucleoli, (single 
invasive tumor cell, left arrow; right arrow points to the tumor) from a wt male without Zn; (h) a well- to- moderately differentiated SCC (all portions 
in subcutaneous area are invasive) from a wt male with Zn treatment. Scale bar = 100 μm. Fhit, murine fragile histidine triad gene; Fhit, human or 
mouse protein; H&E, hematoxylin & eosin; SCC, squamous cell carcinoma; PMA, phorbol myristate acetate.
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7912, irradiated rodent chow 7012). Mice were monitored 
weekly for tumor development and sacrificed after the 
final PMA treatment. Upon experiment termination, skin, 
liver, spleen, and kidney were grossly examined for tumors, 
which were not observed; skin tumors were measured 
and counted. The entire treated skin area was excised 
and cut into three sections that were fixed and processed 
for histology and immunohistochemistry (IHC) studies. 
Tumors (at least 2 mm in diameter) from individual skins 
with adjacent nontumor skin were isolated and separately 
processed for analysis.
To examine the role of inflammation in tumor burden 
reduction by Zn supplementation, we scored Fhit−/− and 
B6 mouse tumors for inflammation on a scale of 0–3 at 
the time of sacrifice.
Histopathological analysis
Tissues were fixed in 10% buffered formalin for 2 days 
and then processed and embedded in paraffin. Skin sec-
tions were cut across all layers and stood on cut- ends 
on slides. Slides were stained with hematoxylin and eosin 
(H&E) for pathological assessment, for enumeration of 
papillomas and carcinomas, or with specific antisera for 
IHC analyses. Skin lesions were graded and enumerated 
by pathologists (RS, JL) who were blinded to treatments. 
This analysis was performed by light microscopy using a 
Nikon Eclipse Ci microscope and photographs taken with 
a Nikon digital sight DSfi1 C camera. Skin tissue with 
two epithelial layers was designated normal, whereas mild 
and severe hyperplasia showed increasingly thickened epi-
thelium. Squamous cell carcinomas were categorized based 
on three differentiation levels: poorly, moderately, and 
well- differentiated.
Immunohistochemical analysis
Based on previous studies of skin cancer induction and 
Zn supplementation, 8- hydroxy- 2′ - deoxyguanosine (8- 
OHdG), and γH2AX were chosen for expression analysis 
in the various treatment groups [14, 27]. Antisera used 
are listed in Table 1, with antigen retrieval and detection 
methods. IHC staining was performed in the histology/
immunohistochemistry Core Lab of the Department of 
Veterinary Biosciences of The Ohio State University, by 
the following procedure: Skin tissue embedded in paraffin 
was cut at 4 μm and placed on positively charged slides; 
slides were deparaffinized by xylene and rehydrated through 
graded ethanol solutions to water. For 8- OHdG, and 
γH2AX, antigen was retrieved by conditions listed in 
Table 1 followed by water washes. Slides were quenched 
for 10 min in a 3% hydrogen peroxide solution to block 
endogenous peroxidase and blocked with Dako serum- free 
protein block (Dako North America, Carpinteria, CA) 
before 30 min incubation with primary antisera in Dako 
antibody at dilutions indicated in Table 1. After washes, 
slides were incubated 30 min with biotinylated secondary 
antisera. Slides were then incubated with Vector RTU 
ABC Elite (Vector laboratory, Burlingame, CA) complex 
for 30 min and were incubated with Dako DAB substrate 
chromogen for 5 min followed by counterstaining in 
hematoxylin for 15 sec. After dehydration through graded 
ethanol solution and xylene, slides were coverslipped.
Statistical analyses
To compare tumor burdens of mice with or without Zn 
supplementation, general linear models with fixed Zn 
treatment, gender, and their interactions were used to 
test overall effect of Zn supplementation for each mouse 
genotype. Poisson regression analysis was also conducted 
as sensitivity analysis to confirm the conclusions are robust 
for the counting data. Weighted averages were calculated 
to compare mice from different genotypes and treatments. 
Comparisons among subgroups (gender) were also con-
ducted based on the model and the P values were adjusted 
using the Tukey–Kramer method. The histopathological 
features of the Zn supplemented and placebo groups were 
compared using Chi- square tests. Statistical tests were 
two- sided and were considered significant at P < 0.05.
Results
Fhit−/− mice exhibit increased skin tumor 
burden
Previous studies showed that Fhit knockout mice are more 
sensitive than wt mice to carcinogen- induced epithelial 
Table 1. Primary antisera and detection methods for immunohistochemical assays.
Antigen Retrieval Primary antiserum Source Description Dilution Secondary Ab
Dako Proteinase K 15 min at RT 8- OHdG Millipore AB5830, goat polyclonal 1:1000 Rabbit anti- goat 1:200
Dako Target Retrieval Solution γ- H2AX Bethyl IHC- 00059 1:100 Goat anti- rabbit 1:200
Dako Proteinase K 5 min at RT MPO Dako A0398, rabbit polyclonal 1:400 Goat anti- rabbit 1:1000
8- OHdG, 8- hydroxy- 2′- deoxyguanosine; IHC, immunohistochemistry.
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tumors of the forestomach and esophagus [14, 26]. 
Therefore, we expected that Fhit−/− mice would also develop 
more NMSC tumors compared to wt B6 mice, a strain 
with low predisposition for spontaneous skin tumors 
(http://www.informatics.jax.org/mtbwi/tumorFrequen-
cyGrid.do). Accordingly, each genotype included two treat-
ment groups of mice, the control and Zn- supplemented 
groups. Control mice received water without Zn, whereas 
the treatment group received Zn- gluconate in drinking 
water, following initial DMBA treatment; 30 weeks after 
initial DMBA treatment, mice were sacrificed, skin tumors 
enumerated, and tissues fixed and processed.
The results, summarized in Table 2, demonstrate that 
unsupplemented Fhit−/− mice exhibited significantly more 
skin tumors following DMBA/PMA treatment than wt 
mice with an average of 16.2 versus 7.6 total tumors/
mouse, respectively (P < 0.001). Female and male Fhit−/− 
mice had similar multiplicities of total tumors (16.5/mouse 
for females and 15.9/mouse for males) whereas there was 
a slight bias for tumors in female wt mice (9.1/mouse 
for females vs. 6.0/mouse in males, P = 0.07).
Skin tumor multiplicity in Fhit−/− mice was 
reduced by Zn supplementation
Zn supplementation significantly reduced total average and 
gender- specific tumor burdens in Fhit−/− mice (see 
Table 2). Fhit−/− mice administered nonsupplemented 
drinking water developed more tumors (average, 16.2/
mouse) compared to those on Zn- gluconate water (10.3/
mouse), a 37% decrease with Zn supplementation 
(P < 0.001). Notably, the tumor burden reductions were 
different for female and male mice: female mice exhibited 
49% reduced tumor burden after Zn treatment versus 
25% for male mice. The tumor burden distribution, that 
is, fractions of tumors of ≤0.5, 1 and ≥2 mm diameter, 
was similar for male and female mice. In the Fhit−/− 
unsupplemented cohort, the distribution (% of tumors 
of various sizes) was 41%, 37%, 21% for females and 
26%, 46%, and 28% for males. Within the Fhit−/− sup-
plemented group, the distribution was 36%, 47%, and 
16% for males and 37.6%, 39%, and 23% for females 
(smallest to largest).
On the other hand, Zn supplementation in wt mice 
did not have an observable effect on overall tumor num-
ber; wt mice without Zn supplementation averaged 7.6 
tumors/mouse, whereas mice with Zn supplementation 
averaged 8.9 tumors/mouse (P = 0.29). The tumor burden 
distribution among unsupplemented and supplemented 
wt mice shows more small tumors in the supplemented 
versus unsupplemented group: tumors of ≤0.5, 1 and 
≥2 mm diameter were 63%, 14%, 23% and 32%, 29%, 
and 39%, respectively, for both males and females within 
the supplemented wt group and 28%, 40%, and 32% for 
males versus 34%, 45% and 21% for females of the Zn- 
unsupplemented wt mice (Table 2). The greatest concen-
tration of small tumors (≤0.5 mm) occurred in the 
supplemented wt male cohort, suggesting that tumors are 
continuing to be initiated in the supplemented wt males. 
This may suggest that the skin cancer- resistant wt males 
exhibit not just a strain bias but also a gender bias, con-
tinuing to develop small tumors that with longer Zn 
treatment would likely regress.
We did observe a gender- specific response to the Zn 
supplementation in wt females (9.1 tumors/mouse for no 
Zn versus 6.9 tumors/mouse for Zn supplemented, 
P = 0.006), as seen in Fhit−/− females. While nonsup-
plemented wt males developed fewer tumors/mouse (6.0) 
than wt females (9.1), male mice developed more, mostly 
small tumors (10.8 total tumors per mouse) with Zn 
Table 2. Effect of Zn supplementation on skin tumor multiplicity in Fhit−/− and wt mice.
Genotype Treatment group n
Total tumors/mouse Number of tumors with size (Mean ± SD)
(Mean ± SD) ≤0.5 mm 1 mm ≥2 mm
B6 wt F 23 9.1 ± 4.3 3.1 ± 2.6 4.1 ± 3.5 1.9 ± 1.6
F + Zn 19 6.9 ± 4.5 2.2 ± 2.3 2.0 ± 1.6 2.7 ± 2.3
M 11 6.0 ± 4.3 1.7 ± 1.6 2.4 ± 2.7 1.9 ± 1.4
M + Zn 10 10.8 ± 5.4 6.8 ± 4.0 1.5 ± 1.3 2.5 ± 2.1
Fhit−/− F 28 16.5 ± 8.9 6.8 ± 4.7 6.1 ± 5.1 3.5 ± 2.5
F + Zn 17 8.5 ± 6.3 3.2 ± 2.4 3.3 ± 3.7 2.0 ± 1.8
M 15 15.9 ± 6.0 4.1 ± 3.6 7.4 ± 4.5 4.4 ± 3.6
M + Zn 17 12 ± 4.6 4.3 ± 3.3 5.6 ± 4.0 2.1 ± 1.9
Statistical analyses showed statistically significant differences in tumor multiplicity (number of tumors per mouse, mean ± standard deviation) in un-
supplemented Fhit−/− versus unsupplemented B6 mice (16.2 tumors in Fhit−/− mice versus 7.6 tumors in wt mice, weighted averages for genotypes 
combining males and females), P < 0.001), as well as in tumor multiplicity in unsupplemented Fhit−/− mice versus Zn- supplemented Fhit−/− mice (16.2 
unsupplemented vs. 10.3 Zn supplemented, P = 0.001). F, female; M, male; B6, C57BL/6J.
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supplementation. The tumor size distribution in wt males 
clearly reflects the predominance of tumors of ≤0.5 mm 
in wt Zn- supplemented mice versus those without Zn 
supplementation (6.8 vs. 1.7/mouse); since a previous study 
in oral carcinogenesis [15] showed that Zn supplementa-
tion caused a shift to a less aggressive tumor phenotype, 
we further analyzed the data excluding the tumors of 
≤0.5 mm diameter. We then saw a decrease in the total 
number of large tumors (>1 mm) for both male and 
female wt mice following Zn supplementation: males, 4.3 
reduced to 4.0; females, 6.0 reduced to 4.7, a decrease 
that is not statistically significant, likely due to the com-
bined resistance of wt mice to skin tumors development, 
the small sample size and the fact that the tumor promo-
tion protocol occurred in parallel with the Zn supple-
mentation. It is highly likely that if the Zn supplementation 
of mice were continued beyond discontinuation of the 
tumor induction protocol, we would have seen a continu-
ing regression of tumors in the supplemented mice versus 
unsupplemented cohorts.
Histopathological analysis of skin lesions
Formalin- fixed, paraffin- embedded skin tumors and treated 
skin regions of all mice from each genotype were pro-
cessed, embedded, mounted, and H&E stained for histo-
pathological analyses. Several sections from each skin 
sample were scored for frequency of papilloma, mild or 
severe hyperplasia, dysplasia, and carcinoma. Results are 
summarized in Table 3 and sections illustrating tissues 
with hyperplasia, dysplasia, and SCC with different dif-
ferentiation level are shown in Figure 1B. Skin SCCs were 
found in all the strain and treatment groups as listed in 
the final column of Table 3 and the incidence of SCCs 
was reduced in each cohort, male and female, by Zn 
supplementation: 35% and 80% of nonsupplemented 
female and male wt mice, respectively, showed SCCs in 
the skin sections examined and these were reduced to 
22% and 20%, respectively, in the Zn- supplemented females 
and males; in the Fhit−/− cohorts, 68% of females and 
53% of males exhibited SCCs in the tissue sections exam-
ined and these SCC incidences were reduced to 58% and 
29%, respectively. The most striking and significant 
 reduction in SCC incidence was observed in the wt male 
cohort (80–20%, P = 0.023); it is also very striking that 
in the untreated wt males, no papillomas were observed, 
as if all tumors progressed to SCCs, whereas the Zn treat-
ment slowed this progression significantly, leaving more 
papillomas that have not progressed. Also, the overall SCC 
incidence (for both strains, males plus females) was reduced 
by Zn supplementation, achieving statistical significance 
in wt strain (P = 0.035) and it is likely that continuation 
of Zn supplementation beyond termination of the 30- week 
PMA tumor promotion treatments would have eliminated 
the skin SCCs entirely. Figure 1A illustrates the results 
of the 20- week pilot tumor induction experiment illustrat-
ing the tumor initiation latency differences among the 
mouse strains and genders, showing that the B6 mice 
showed a longer latency period relative to the Fhit- deficient 
mice.
The inflammatory process in skin of 
unsupplemented and Zn- supplemented mice
Since inflammation is a contributing factor to carcino-
genesis [28], we wanted to determine if Zn supplementa-
tion reduced tumor burden via attenuation of 
inflammation. We scored Fhit−/− and B6 for inflammation 
Table 3. Histopathological analysis of skin lesions.
Genotype Treatment group
No. of mice 
examined
Incidence (%)
Papilloma Mild hyperplasia Severe hyperplasia Dysplasia SCC
B6 wt F 23 4/23 (17%) 0 5/23 (22%) 6/23 (26%) 8/23 (35%)*
F + Zn 18 5/18 (28%) 1/18 (6%) 3/18 (16%) 5/18 (28%) 4/18 (22%)
M 10 0 0 0 2/10 (20%) 8/10 (80%)**
M + Zn 10 4/10 (40%) 1/10 (10%) 0 3/10 (30%) 2/10 (20%)**
Fhit−/− F 28 3/28 (11%) 0 0 6/28 (21%) 19/28 (68%)*
F + Zn 17 3/17 (18%) 1/17 (6%) 2/17 (12%) 1/17 (6%) 10/17 (58%)
M 15 5/15 (34%) 0 0 2/15 (13%) 8/15 (53%)
M  +  Zn 17 3/17 (18%) 0 4/17 (24%) 5/17 (29%) 5/17 (29%)
SCC incidence includes both carcinoma in situ and squamous cell carcinoma – *unsupplemented Fhit−/− female versus unsupplemented wt female 
(68% vs. 35%), P = 0.026; **Zn supplementation led to a reduced carcinoma incidence in wt males (20% vs. 80%), P = 0.023. Additionally, the total 
M+F wt SCC burden was significantly reduced in the mice with Zn supplementation (6/28 SCCs or 18% in Zn- supplemented wt mice vs. 16/33 SCCs 
or 48% in unsupplemented wt mice, P = 0.035); in Fhit−/− mice, with more total M  +  F tumors in more mice, there was a decrease in SCCs with Zn 
supplementation, trending toward significance (15/34 SCCs or 44% with Zn supplementation vs. 27/43 or 63% SCCs without Zn supplementation, 
P = 0.11). Fisher’s exact test, two- tailed. F, female; M, male; SCC, squamous cell carcinoma.
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at the time of sacrifice on a scale of 0–3 (Fig. 2A). As 
shown in Figure 2B, B6 male skin tumors exhibited sig-
nificant reduction in inflammation with Zn supplementa-
tion (from 1.55 ± 0.68 without Zn to 0.90 ± 0.32 with 
Zn supplementation, P = 0.018), a result suggesting that 
Zn supplementation reduces SCC incidence in B6 males 
(Table 3) by lessening inflammation. Fhit−/− mice did 
not show statistically significant changes in inflammation 
scores after supplementation. This suggests that the 
observed reductions in tumor multiplicity via Zn sup-
plementation in Fhit−/− mice involved mechanisms other 
than or in addition to effects on inflammatory 
processes.
Expression of DNA damage response 
markers in skin tissues of Zn- supplemented 
mice
Although the mechanism of DMBA/PMA- induced tumo-
rigenesis is not fully elucidated, it is thought to be partially 
through induction of DNA damage. To determine if the 
reduced level of skin lesions in Zn- supplemented subjects 
was accompanied by changes in the level of expression 
of DNA damage markers, we assessed the presence of 
8- OHdG adducts and γH2AX expression by IHC staining 
(Fig. 3). Focal γH2AX expression is a marker of DNA 
damage at replication forks [29], whereas 8- OHdG is an 
Figure 2. Inflammation in wt and Fhit−/− DMBA/PMA- induced skin tumors. (A) H&E sections (a–e) showing (a) inflammation grade 0–1 with hyperplasia 
from a Fhit−/− female with Zn; (b) inflammation grade 2 with hyperplasia in skin epithelium from a Fhit−/− male with Zn; (c) inflammation grade 3 in 
hyperplasia from a Fhit−/− female without Zn supplementation; (d) inflammation in skin SCC in situ with marked fibroblast hyperplasia (thick arrow) 
and basal cell proliferation (thin arrow) from a wt female without Zn; (e) inflammation grade 0–1 with increased mast cells (mastocytosis, arrow) in 
skin with hyperplasia from a wt female without Zn; (f) showing antimyeloperoxidase immunostained section from a Fhit−/− female without Zn 
supplementation, with SCC and marked inflammation with increased mast cells, arrows point to immunostained positive mast cells; (g) 
antimyeloperoxidase immunostained severe hyperplasia from a Fhit−/− male with Zn treatment, showing reduced neutrophil and rare mast cell (arrow). 
Scale bar = 100 μm. (B) Inflammation score in wt and Fhit−/− skin tumors from males and females with or without Zn supplementation (error 
bars = SD, n = 10–27/cohort).DMBA, dimethylbenzanthracene; PMA, phorbol myristate; SCC, squamous cell carcinoma. 
A
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oxidized derivative of deoxyguanosine and is a major 
product of DNA oxidation [30]. As shown in Figure 3, 
Zn supplementation significantly reduced 8- OHdG accu-
mulation (P = 0.0008) and γH2AX expression (P = 0.0008) 
in lesions of Fhit−/− mouse skin, suggesting that Zn- 
associated reduction in level of reactive oxygen species 
production and reduction in level of DNA damage con-
tributed to the reduced tumor burden in skin of sup-
plemented mice.
Discussion
Dietary Zn is essential for proper physiological develop-
ment and performance of numerous physiological functions 
including growth, reproduction, immune response, preg-
nancy, and prenatal development [9, 31, 32]. Response 
to Zn ingestion exhibits a U- shaped dose–response curve 
due to adverse effects associated with too little or too 
much Zn in vital tissues and organs. Rare cases of Zn 
toxicity, due to application of Zn- based denture adhesives 
in one particular report, can lead to systemic accumula-
tion of high levels of Zn, which in turn may cause patho-
logic copper- deficiency and neurologic signs [33], these 
side effects were reversible on elimination of the source 
of Zn excess. However, the predominant area of research 
regarding Zn has been in deficiency, as it is estimated 
that approximately two billion people or one- third of the 
world’s population is affected by inadequate sources of 
dietary Zn [34]. Geographically, this prevalence corresponds 
to regions in Africa, India, Southeast Asia, and Latin 
America [35]. Studies have shown that Zn- deficient popu-
lations receiving supplemental Zn have reductions in the 
incidences of acute lower respiratory infections, morbidity 
associated with diarrhea, and increased weight gain in 
infants and children [36]. In addition, numerous epide-
miological studies in humans, as well as experimental 
rodent models, have demonstrated that Zn- deficiency 
contributes to cancer development [14, 37, 38].
We were interested in determining if mild Zn sup-
plementation may contribute to reduction in skin cancer 
burden in Zn- sufficient subjects, using a preclinical mouse 
model and carcinogen induction of skin cancer. We 
employed Fhit−/− mice because of their sensitivity to car-
cinogen induction of various tumor types, and B6 mice 
as wt control cohort. We have previously reported that 
Fhit deficiency causes genome instability that is undetected 
by cellular checkpoints [24], providing an optimal envi-
ronment for selection and clonal expansion to survive 
various stressors [25]. For instance, we have shown that 
Fhit−/− mouse kidney cells survive acute DMBA treatment 
and chronic severe nutritional stress whereas wt cells do 
not [25]. Therefore, the enhanced survival and mild 
genomic instability characteristic of Fhit- deficient mice 
and tissues allow them to serve as appropriate models 
for carcinogen- induced cancer models. In line with our 
hypothesis, we found that Fhit−/− mice showed significantly 
more carcinogen- induced tumors than wt mice 
(P < 0.001). We expect that the skin of Fhit−/− mice 
treated with the DMBA/PMA induction protocol would 
also display increased single- base substitutions, copy num-
ber alterations and aneuploidy, representative of the genome 
instability seen in Fhit knockout mice [25, 39], compared 
to the skin of the similarly treated control mice.
The data also confirmed our second hypothesis that 
Fhit−/− mice would exhibit statistically significant reduc-
tions in tumor burden with Zn supplementation following 
a DMBA/PMA induction protocol, suggesting a potential 
role for Zn supplementation in NMSC prevention. 
Interestingly, there was a gender bias in the effect of Zn 
supplementation in this model study, with supplemented 
female mice showing lower tumor burdens and thus appear-
ing more sensitive to Zn supplementation compared to 
Zn- supplemented males (49% reduction in females vs. 25% 
reduction in males). Our data agree with a growing body 
of evidence of a distinct gender bias in human and rodent 
models of skin cancer: biases that are not consistent across 
species. In humans, men exhibit a twofold higher incidence 
of NMSC than women. Sociological factors such as increased 
occupational sun exposure and less use of sun protective 
techniques among men are likely contributing factors. 
However, studies using experimental mouse models, where 
Figure 3. Zn supplementation reduces 8- OHdG and γH2AX expression 
in skin tumors in Fhit−/− mice. Bar charts showing percentage of (A) 
γH2AX- positive cells; (B) 8- OHdG- positive cells. The bar charts represent 
mean +/−SD. n = 7 for each treatment, compared with Fhit−/− without 
Zn, P = 0.0008 for γH2AX and P = 0.0008 for 8- OHdG.
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subjects are controlled for sun exposure and cancer moni-
toring, reveal significant biological differences between 
genders that contribute to the development of NMSC. For 
example, UVA radiation (320–400 nm) has an endogenous 
protective role by antagonizing UVB- induced immunosup-
pression in a gender- specific way, through the ER- β path-
way. That is, males, naturally deficient in estrogen and 
ER signaling, do not exhibit reductions in contact hyper-
sensitivity induced by solar stimulated radiation, suggesting 
that females are more protected than males to NMSC. 
However, the same study demonstrated that male mice 
exposed to both UVA and UVB had less inflammatory 
edema compared to females due to their naturally thicker 
skin (presumably due to increasing thickness of the dermis 
and subdermal muscle layer) and decreases in levels of 
proinflammatory IL- 6 specific to males [40]. In another 
study, Sullivan et al [41]. proposed that lower endogenous 
catalase activity in males compared to females is responsible 
for increased NMSCs observed in male mice exposed to 
UVB radiation. Therefore, it is not surprising that we also 
see differences in the effects of Zn supplementation on 
NMSC in our model. Further studies will be needed to 
determine the causative factors for this gender disparity 
in response to DMBA and PMA initiation and promotion 
of carcinogenesis, though we show a clear association of 
tumor burden reductions with Zn supplementation in 
females for both genotypes.
Our observation that B6 male mice exhibited more 
tumors with Zn supplementation (10.8) than without (6.0), 
due to the increase in very small tumors (≤0.5 mm) in 
Zn- supplemented B6 males (63%) versus unsupplemented 
males (28%), is also likely related to small sample size. 
Since it is thought that Zn supplementation works by 
suppressing the progression of neoplasia rather than inhi-
bition of tumor initiation, the small tumors in the sup-
plemented−/− males may be due to persistence of small 
preneoplasias that are blocked in an early hyperplastic stage 
and cannot progress. In fact, if we remove the small tumors 
(≤0.5 mm) of this cohort from consideration, we observe 
a decrease in tumor burden with Zn supplementation.
The most important finding from this study, summa-
rized in Table 3, is that each of the cohorts of mice, wt 
and Fhit- deficient, male and female, showed reductions 
in the incidence of SCCs in the Zn- supplemented groups, 
most significantly in the male wt mice, with a reduction 
of 80% of mice with SCCs without Zn supplementation 
to 20% with SCCs in the supplemented group, (P = 0.023); 
interestingly these supplemented B6 male mice showed 
the highest number of small tumors and papillomas, as 
if these small tumors did not progress or regressed from 
SCCs. A larger study with Zn supplementation carried 
on for weeks after ending the PMA treatment would likely 
answer several of the questions raised by the results.
As a cofactor of over 300 mammalian proteins, dietary 
Zn has roles in a number of physiological processes [9, 
32]. Thus, we wanted to investigate mechanisms that might 
account for the significant reductions we observed in 
tumor burdens of Zn- supplemented mice. First, we evalu-
ated differences in inflammation grades in Fhit−/− mice 
Zn supplemented or not. Inflammation, particularly 
chronic inflammation, has been shown to predispose an 
individual to cancer [28]. In fact, the widely used DMBA/
PMA model of NMSC induction is based on chronic 
inflammation and the resultant production of inflamma-
tory mediators [42]. Zn is also known to help maintain 
the activity of cells involved in the immune response and 
inflammation, such as natural killer cells, neutrophils, and 
macrophage;[28] therefore it was natural to presume that 
Zn supplementation may decrease tumor burdens by less-
ening the degree of inflammation caused by DMBA/PMA 
protocol. However, we did not observe a statistically sig-
nificant difference in inflammation grades in Fhit−/− Zn- 
supplemented and - unsupplemented groups. We then 
examined markers of DNA damage: 8- OHdG adducts and 
γH2AX expression by IHC staining in Zn- supplemented 
and - unsupplemented groups, to determine if Zn lessened 
DNA damage through prevention of oxidative damage. 
We report a significant reduction in 8- OHdG adducts, 
markers of DNA oxidation, and γH2AX foci, markers of 
DNA double strand breaks, in supplemented Fhit−/− mice, 
suggesting that the method whereby Zn supplementation 
reduces tumor burden in Fhit−/− mice is by attenuation 
of oxidative damage. The precise antioxidant effect of Zn 
remains unclear, although two potential mechanisms exist: 
(1) Zn is an essential component of CuZnSOD, an enzyme 
that removes the superoxide anion in reactive oxygen 
species, and (2) Zn prevents the oxidation of sulfhydryl 
groups in redox- active transition metals [43]. Further 
studies are needed to determine if either or both of these 
mechanisms are responsible for the reductions in 8- OHdG 
adducts and γH2AX foci, but the data does suggest that 
Zn supplementation decreases tumor burden through DNA 
damage prevention, allowing for the identification of an 
anti- inflammatory therapeutic as a possible synergistic 
regimen to Zn supplementation.
The results of this study suggest that mild Zn sup-
plementation may be helpful for preventing the progression 
of NMSCs, even in Zn- sufficient individuals, possibly in 
combination with other preventive treatments currently 
under investigation in UV or DMBA/PMA induction 
models, some showing promise [44–49]. Further studies 
are needed to define mechanisms that enable dietary Zn 
supplementation to reduce tumor burdens in Fhit−/− mice, 
perhaps with a focus on experiments aimed at evaluating 
differences in responses in male and female mice, since 
females displayed the most emphatic reductions. We believe 
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that in clinical prevention or therapeutic trials in humans, 
particularly in cohorts predisposed to multiple skin cancers, 
it would be beneficial to include very inexpensive Zn 
supplementation in trial arms, to confirm its role in pre-
vention of NMSC progression.
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